about
The Utility of Metabolic Imaging by 18F-FDG PET/CT in Lung Cancer: Impact on Diagnosis and StagingTargeted therapies in development for non-small cell lung cancerClassification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclassesDevelopment of a rabbit pleural cancer model by using VX2 tumors.Parthenolide suppresses non-small cell lung cancer GLC-82 cells growth via B-Raf/MAPK/Erk pathwayDosimetric evaluation of heterogeneity corrections for RTOG 0236: stereotactic body radiotherapy of inoperable stage I-II non-small-cell lung cancer.Signaling networks associated with AKT activation in non-small cell lung cancer (NSCLC): new insights on the role of phosphatydil-inositol-3 kinase.Identification of miR-374a as a prognostic marker for survival in patients with early-stage nonsmall cell lung cancer.Proteomics-based identification of proteins secreted in apical surface fluid of squamous metaplastic human tracheobronchial epithelial cells cultured by three-dimensional organotypic air-liquid interface method.Methylation markers of early-stage non-small cell lung cancerEnhanced heme function and mitochondrial respiration promote the progression of lung cancer cellsA five-gene and corresponding protein signature for stage-I lung adenocarcinoma prognosis.Short-term exposure to tobacco toxins alters expression of multiple proliferation gene markers in primary human bronchial epithelial cell cultures.The stimulatory activity of plasma in patients with advanced non-small cell lung cancer requires TLR-stimulating nucleic acid immunoglobulin complexes and discriminates responsiveness to chemotherapy.Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluationIn-vivo kinetics of inhaled 5-aminolevulinic acid-induced protoporphyrin IX fluorescence in bronchial tissue.Overexpression of OLC1, cigarette smoke, and human lung tumorigenesis.Loss of transforming growth factor beta type II receptor increases aggressive tumor behavior and reduces survival in lung adenocarcinoma and squamous cell carcinoma.Serum LAMC2 enhances the prognostic value of a multi-parametric panel in non-small cell lung cancer.Mutational analysis of the insulin-like growth factor 1 receptor tyrosine kinase domain in non-small cell lung cancer patients.Histologic patterns and molecular characteristics of lung adenocarcinoma associated with clinical outcome.Identification of gene signatures and molecular markers for human lung cancer prognosis using an in vitro lung carcinogenesis system.Differential expression of RBM5, EGFR and KRAS mRNA and protein in non-small cell lung cancer tissues.Second-Line Therapy of Small-Cell Lung Cancer: Topotecan Compared to a Combination Treatment with Adriamycin, Cyclophosphamide And Vincristine (ACO) - a Single Center ExperienceMaintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe.Stereotactic ablative body radiotherapy (SABR) for primary and secondary lung tumours.Reduction of normal lung irradiation in locally advanced non-small-cell lung cancer patients, using ventilation images for functional avoidance.Targeting HER1/EGFR in cancer therapy: experience with erlotinib.Staging and diagnosis of non-small cell lung cancer: invasive modalities.Identification of a panel of sensitive and specific DNA methylation markers for squamous cell lung cancerPrognostic Factors as a Function of Disease-free Interval After Definitive (Chemo)radiation for Non-Small Cell Lung Cancer Using Conditional Survival Analysis.Controversies in the management of stage IIIA non-small-cell lung cancer.Charged particle radiotherapy at the Hyogo Ion Beam Medical Center: Characteristics, technology and clinical resultsClinical value of circulating endothelial cells and of soluble CD146 levels in patients undergoing surgery for non-small cell lung cancer.Aberrant Signaling through the HER2-ERK1/2 Pathway is Predictive of Reduced Disease-Free and Overall Survival in Early Stage Non-Small Cell Lung Cancer (NSCLC) Patients.Gene Expression-Based Approaches in Differentiation of Metastases and Second Primary TumourIncidence and predictors of Bone Metastases (BM) and Skeletal-Related Events (SREs) in Small Cell Lung Cancer (SCLC): A Swiss patient cohort.Effects of maslinic acid on the proliferation and apoptosis of A549 lung cancer cells.5-Fluorouracil preferentially sensitizes mutant KRAS non-small cell lung carcinoma cells to TRAIL-induced apoptosis.Moving forward with circulating tumor cells and lung cancer
P2860
Q27001239-FD98E5CE-9471-4069-B1DF-50C72FB4EC76Q27022852-C008AF97-B656-45F6-B944-A70F2A765E48Q29616071-D69988DA-D536-4DA9-B456-BF0FC318BA32Q33347764-BA9BB629-96C0-40CA-88B7-3E8F12C69A71Q33618711-B0251FCC-4CF9-42E0-916C-5DCD4A2429F4Q34024586-46CB028D-7957-4A66-BF68-E2EAB8C1705BQ34170007-46D731B8-F971-4B1C-BC3C-1337BB2EFE95Q34199722-A8605609-D6A4-4429-A5B3-EAF48330A9D6Q34216404-AFED874D-854F-42A3-8A74-E199FBD9812FQ34328293-C5758AC0-6443-4166-8AC7-3290E4C08FA0Q34737397-BC5A98ED-25E8-4EB3-9361-7DA5CC2EF3B7Q34814723-BFB09D15-C823-41D5-8FD2-D6E9C78F6096Q35110036-6562217C-97BE-4900-92A7-60DCAC0E513FQ35189391-400BE106-DDAF-40FC-8B33-DAFE56EA66E4Q35770249-FFAA30DE-3D2D-42B6-9164-3B6F82BA9165Q35791264-A80B75C5-9A76-4342-9BD8-537D337BEE9FQ35821113-E0C6B68C-5E46-4597-B9C1-9DB0F318B125Q35894697-87A8C6EC-2367-412D-ADED-4294C6481DCAQ35909576-11FAEA17-1671-4D14-A51B-434DA0A539D3Q35948040-348C11E4-DA28-4318-B85E-D59CBAB9D57AQ36013991-A3C98762-DEE1-48B7-B9DD-2F8BBA98B5FFQ36055579-FA676C4E-7BEF-4D68-AB52-17E61EF6996CQ36112781-12BD57C9-293C-4920-9EE3-95BD2FD6D37CQ36190145-C925623F-874B-48FC-BC42-CBE4A4143036Q36248579-3897ADC7-64C0-46AF-92BF-BD99653DCFA1Q36286591-95DB7B12-910D-4295-A7AA-06920B0CE5DCQ36374803-5C58C881-E897-418A-AA80-954B9AFB196EQ36429516-D6E89CA3-B046-45E8-B434-71C249E4276DQ36735015-F8C69319-9466-4547-BC5B-E18BEF45C34FQ36791714-5F8009D0-44ED-4903-A99D-482E95DC24B2Q36863492-22ED53BD-708E-4617-AEF1-8F0FC4B256D9Q37338248-C2F93E3A-F78E-4F7F-B4EE-E13923EA7923Q37373369-EBADB059-5E04-4653-8B6D-B48856278BB4Q37632126-454D74A5-DF9B-43A4-B3FF-653E953BE4F1Q37667783-F1090FBF-7B00-4367-AB3C-431978DFA2C8Q38505296-5F8F8942-8F55-454D-A568-52DCE7ED0C82Q38791807-C8AB89FF-6432-4357-8E97-1223A4DAD1DEQ38819334-BD39BB41-8718-4B69-A1C7-70D775E9BD4DQ38858308-CAFECCD1-DFBF-4D85-99FB-B1B60036541CQ42008010-6AF29573-7C97-4FF7-B5B3-CFC49C822E2D
P2860
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
The international system for staging lung cancer.
@en
type
label
The international system for staging lung cancer.
@en
prefLabel
The international system for staging lung cancer.
@en
P1476
The international system for staging lung cancer.
@en
P2093
Mountain CF
P304
P356
10.1002/(SICI)1098-2388(200003)18:2<106::AID-SSU4>3.0.CO;2-P
P577
2000-03-01T00:00:00Z